首页> 外文期刊>Circulation: An Official Journal of the American Heart Association >Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry.
【24h】

Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry.

机译:在慢性肾病患者中使用基于循证疗法的基于循环抬高心肌梗死和非ST段抬高心肌梗塞的循证疗法:来自国家心血管数据急性冠状动脉治疗和干预结果网络登记处的报告。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Chronic kidney disease (CKD) is a risk factor for myocardial infarction (MI) and death. Our goal was to characterize the association between CKD severity and short-term outcomes and the use of in-hospital evidence-based therapies among patients with ST-segment elevation MI (STEMI) and non-ST-segment elevation MI (NSTEMI). METHODS AND RESULTS: The study sample was drawn from the Acute Coronary Treatment and Intervention Outcomes Network registry, a nationwide sample of STEMI (n=19 029) and NSTEMI (n=30 462) patients. Estimated glomerular filtration rate was calculated with the Modification of Diet in Renal Disease equation in relation to use of immediate (first 24 hours) therapies and early (first 48 hours) cardiac catheterization as well as in-hospital major bleeding events and death. Overall, 30.5% and 42.9% of patients with STEMI and NSTEMI, respectively, had CKD. Regardless of MI type, patients with progressively more severe CKD had higher rates of death. For STEMI, the odds ratio for stage 3a, 3b, 4, and 5 CKD compared with patients with no CKD was 2.49, 3.72, 4.82, and 7.97, respectively (P(trend)<0.0001). For NSTEMI, the analogous odds ratios were 1.81, 2.41, 3.50, and 4.09 (P for trend <0.0001). In addition, patients with progressively more severe CKD were less likely to receive immediate evidence-based therapies including aspirin, beta-blockers, or clopidogrel, were less likely to undergo any reperfusion (STEMI) or revascularization (NSTEMI), and had higher rates of bleeding. CONCLUSIONS: Reports over the past decade have highlighted the importance of CKD among patients with MI. Data from this contemporary cohort suggest that patients with CKD still receive fewer evidence-based therapies and have substantially higher mortality rates.
机译:背景:慢性肾病(CKD)是心肌梗死(MI)和死亡的危险因素。我们的目标是在CKD严重程度和短期结果之间的关联,以及在ST段抬高Mi(Stemi)和非ST-STEMI升高MI(NSTemi)中使用内外循证疗法的使用。方法和结果:从急性冠状动脉治疗和干预结果中汲取的研究样本,网络注册表,患有STEMI(n = 19 029)和NSTEMI(n = 30 462)患者的全国范围内。根据使用立即(前24小时)疗法和早期(前48小时)心脏导管插入和死亡的饮食,估计肾小球过滤速率计算肾脏疾病方程的改性。总体而言,30.5%和42.9%的患者分别具有CKD。无论MI型如何,逐渐严重的CKD患者都有更高的死亡率。对于Stemi,与NO CKD患者相比,阶段3A,3B,4和5 CKD的比率分别为2.49,3.72,4.82和7.97(P(趋势)<0.0001)。对于NStemi,类似的差距为1.81,2.41,3.50和4.09(P用于趋势<0.0001)。此外,逐渐严重的CKD患者不太可能接受立即基于循证的疗法,包括阿司匹林,β-阻滞剂或氯吡格雷,不太可能经历任何再灌注(STEMI)或血运重建(NSTEMI),并且具有更高的速率流血的。结论:过去十年的报道突出了CKD在MI患者中的重要性。来自这种当代队列的数据表明,CKD的患者仍然收到较少的基于循证疗法,并且具有显着提高的死亡率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号